Axcella Health Inc

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative, and liver conditions.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company's multi-targeted oral product candidate for the treatment of NASH. “NASH is the quintessential complex disease, involvin

Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125

Axcella Health's (AXLA) CEO Bill Hinshaw on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021. The company will host a conference call at 8:30 a.m. ET that morning. The conference call webcast will be available in the Investors & News secti

Axcella to Report First Quarter 2021 Financial Results on May 6, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company's product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE): Title: A Novel, Precision-Engineered Amino Acid Composition, AXA1665, is S

Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021

Axcella Health Inc (NASDAQ: AXLA) is a clinical-stage biotechnology company focused on endogenous metabolic modulators, or EEMs, said Axcella Health CEO Bill Hinshaw Thursday on Benzinga's YouTube show "Power Hour." Axcella Health has two "rapidly progressing" Phase II late-stage clinical development programs, he said.

Exclusive: Axcella Health Aims To Become The Standard Of Care

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has achieved a key milestone with U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for AXA1125, enabling the company to proceed directly into a Phase 2b clinical trial. AXA1125 is Axcella's multi-tar

Axcella Announces AXA1125's IND Clearance for the Treatment of NASH

Axcella Health's (AXLA) CEO Bill Hinshaw on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. “The year 2020 was a key inflection point for Axcella as we completed multiple clinical studies with positive results and shifted our full attenti

Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and full year 2020 financial results and other business updates on March 17, 2021. The company will host a conference call at 8:30 a.m. ET that morning. The conference call webcast will be available in the Investor

Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company's President of Research and Development. In this role, Dr. Schecter will oversee all of the company's research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakrava

Axcella Announces Alison D. Schecter, M.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced three upcoming presentations at the NASH-TAG 2021 Conference, which is taking place March 11-13. Among the information to be shared by Axcella at this event will be clinical data regarding AXA1125, the company's multi-targeted product candidate for nonalcoh

Axcella Announces Upcoming Presentations at NASH-TAG 2021

Codiak Biosciences

Denali Therapeutics

Evelo Biosciences Inc

Foghorn Therapeutics

Kaleido Biosciences Inc

Seres Therapeutics

Moderna

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will participate in the following upcoming investor conferences: SVB Leerink 10th Annual Global Healthcare Conference: The company's fireside chat will be webcast on February 26, 2021 at 9:20 a.m. ET. H.C. Wainwright Global Life Sciences Con

Axcella to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced clearance of the company's first investigational new drug (IND) filing and provided an update on its product candidates, research and development activities and expected milestones for 2021. “The year 2020 was a time of tremendous accomplishment for Axcella

Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the J.P. Morgan 2021 Healthcare Conference on January 14, 2021 at 10:00 a.m. ET. A live audio webcast of this discussion will be available on the “Investors & News” section of the company's website, www.axcellahealt

Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

CytomX Therapeutics

Magenta Therapeutics Inc

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 4 Sizzling Biotech Stocks to Buy That Are Under $10

With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Axcella Health Inc. (NASDAQ:AXLA).

Where Do Hedge Funds Stand On Axcella Health Inc. (AXLA)?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today shared details about the company's poster presentations at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually today through November 16, 2020. Both presentations feature dat

Axcella Presents Data for AXA1125 at The Liver Meeting® 2020

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q3 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2020 and provided a business update. “Recent accomplishments serve as further validation of the strength of Axcella's execution amid the COVID-19 pandemic as well as its clinical and regulatory app

Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update

Axcella (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Axcella (AXLA) Might Surprise This Earnings Season

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter financial results and other business updates on November 12, 2020. The company will host a conference call at 8:30 a.m. ET that morning. The conference call webcast will be available in the Investors & News sect

Axcella to Report Third Quarter 2020 Financial Results and Hold Conference Call on November 12, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 13-16, 2020. These presentations will include key data from the co

Axcella Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced a new publication detailing the potential for the development of EMM compositions that simultaneously target multiple biological pathways and address unmet needs in a range of complex diseases. The publication in iScience is now available online. Amino acid

New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)

--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatiti

News for Axcella Health Inc Stock (AXLA)